Stay updated on SBRT +/- Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the SBRT +/- Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the SBRT +/- Pembrolizumab in NSCLC Clinical Trial page
- Check3 days agoChange DetectedThe history version now includes new core content sections: Adverse Events, Outcome Measures, Baseline Characteristics, Participant Flow, Arms and Interventions, and Study Status. These updates expand the data on safety, outcomes, and trial design for NCT03924869 (version dated 2025-12-11, preceding version 2025-11-24, entry 167).SummaryDifference0.2%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.2.0 was removed from the Record History page.SummaryDifference0.0%

- Check31 days agoChange DetectedThe NIH funding/status notice in the page footer was removed, a non-functional site-wide update that does not affect core trial data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check46 days agoChange DetectedThe new screenshot shows the record history with version entries that appear identical to the previous image, indicating no substantive changes to the study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check74 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference5%

- Check81 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

Stay in the know with updates to SBRT +/- Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SBRT +/- Pembrolizumab in NSCLC Clinical Trial page.